<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03051087</url>
  </required_header>
  <id_info>
    <org_study_id>LG-GNCL001</org_study_id>
    <nct_id>NCT03051087</nct_id>
  </id_info>
  <brief_title>To Compare and Evaluate the Efficacy and Safety of Ganilever PFS(Prefilled Syringe) and Orgalutran®</brief_title>
  <official_title>A Multicenter, Randomized, Treated-controlled, Parallel, Open Label Study to Compare and Evaluate the Efficacy and Safety of Ganilever PFS and Orgalutran® in Infertility Women for Assisted Reproductive Technologies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      to compare and evaluate the efficacy and safety of Ganilever PFS and Orgalutran® in
      infertility women for assisted reproductive technologies
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2016</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of eggs taken</measure>
    <time_frame>about 10 days after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with LH (luteinizing hormone) rise &gt; 10 mIU/mL</measure>
    <time_frame>about 8~9 days after randomization (visit 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oocyte quality</measure>
    <time_frame>Day of oocyte retrieval (about 10 days after randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follitrope® PFS total dose and days</measure>
    <time_frame>During 8~9 days after randomization (until administration hCG)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ganilever PFS or Orgalutran® total dose and days</measure>
    <time_frame>From 4~5 days after randomization to 8~9 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fertility rate (%)</measure>
    <time_frame>Day of oocyte retrieval (about 10 days after randomization)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation rate (%)</measure>
    <time_frame>About 4~5 weeks after Embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy (%)</measure>
    <time_frame>About 2 weeks after oocyte retrieval</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy (%)</measure>
    <time_frame>About 4~5 weeks after Embryo transfer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy (%)</measure>
    <time_frame>About 10~11 weeks after oocyte retrieval</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">288</enrollment>
  <condition>Controlled Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>Ganilever (ganirelix acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prefilled syringe / 0.25mg/0.5mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orgalutran (ganirelix acetate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prefilled syringe / 0.25mg/0.5mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ganirelix acetate</intervention_name>
    <arm_group_label>Ganilever (ganirelix acetate)</arm_group_label>
    <arm_group_label>Orgalutran (ganirelix acetate)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  An adult female between the ages of 20 and 39 at the time of screening

          -  Patients whose mean menstrual cycle was between 25 and 35 days

          -  Patients whose FSH (follicle stimulating hormone) concentration does not exceed 13 mIU
             / mL at screening

          -  Patients diagnosed with infertility due to one or more of the following A. Trouble
             Factors B. Male Factors C. Unexplained D. Uterine factors

          -  Patients with previous IVF experience less than 3

          -  Patient who signed the written consent after hearing the explanation of the purpose,
             method and effect of the clinical trial

        Exclusion Criteria:

          -  If the sperm donor (spouse or non-spouse) is a severe male factor (Non obstructive
             azoospermia)

          -  Patients who were diagnosed as PCOS (polycystic ovary syndrome) during screening

          -  Patient with abnormal uterine bleeding during screening

          -  Patients diagnosed with primary ovarian failure

          -  Patients who has ovarian cysts that are not related to PCOS during screening

          -  Patients with tubal hydrops

          -  Patients with untreated non-reproductive endocrine disease

          -  Patients with a deformity of the reproductive organs that can not be conceived, or
             fibroids of the uterus that can not be conceived (only for submucosal myoma)

          -  Patients with less than 2 ovaries (0 or1)

          -  Patients with ovarian, breast, uterus, hypothalamus, or pituitary malignancies

          -  Patients with BMI &lt;18 or BMI&gt; 30

          -  Patients with an LH concentration of less than 1.2mIU / mL during screening

          -  Poor ovarian responder by bologna criteria

          -  Patients with moderate or severe renal impairment (creatinine clearance &lt;60 mL / min)
             or liver function impairment (ALT or AST,&gt; 5 times normal)

          -  Patients who experienced Grade 4 or higher OHSS (ovarian hyperstimulation syndrome)
             before

          -  Patients who are contraindicated for pregnancy

          -  Patients being pregnant or lactating

          -  Patients with hypersensitivity to IP

          -  Patients who have participated in other medication-related clinical trials since
             enrollment in this study, or have participated in other clinical trials within 3
             months (90 days) before enrolling in this trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>So La Park</last_name>
    <email>pphhoo@lgls.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHA Women's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>So La Park</last_name>
      <email>pphhoo@lgls.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2017</study_first_submitted>
  <study_first_submitted_qc>February 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2017</study_first_posted>
  <last_update_submitted>February 8, 2017</last_update_submitted>
  <last_update_submitted_qc>February 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

